STOCK TITAN

AVITA Medical Inc - RCEL STOCK NEWS

Welcome to our dedicated news page for AVITA Medical (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on AVITA Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AVITA Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AVITA Medical's position in the market.

Rhea-AI Summary
AVITA Medical, a regenerative medicine company, will announce its first quarter 2024 financial results on May 13, 2024. The company specializes in devices for wound care management and skin restoration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
-
Rhea-AI Summary
AVITA Medical Updates Expected Commercial Revenue for Q1 2024, Reaffirms Full-Year Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.32%
Tags
-
Rhea-AI Summary
AVITA Medical, Inc. submits response to FDA for additional information on RECELL GO™, positioning for FDA approval on May 30, 2024, and product launch on May 31, 2024. CEO Jim Corbett anticipates broader adoption of RECELL with the new product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
Rhea-AI Summary
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced that David O’Toole, CFO, will present at TD Cowen’s 44th Annual Health Care Conference. The presentation will be available via live audio webcast on March 5, 2024, at 9:50 a.m. ET. A replay will be accessible on the company's website for 90 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.47%
Tags
conferences
-
Rhea-AI Summary
AVITA Medical, Inc. (RCEL) announces an investor webinar briefing and presentation covering financial highlights, business updates, 2024 revenue guidance, and a Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences
-
Rhea-AI Summary
AVITA Medical Reports Strong Financial Results and Outlines Future Milestones for 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
Rhea-AI Summary
AVITA Medical, Inc. will report its fourth quarter and full year 2023 financial results on February 22, 2024, and host a conference call to discuss its financial results, business highlights, 2024 revenue guidance, and achievement of cashflow breakeven and GAAP profitability in a specific quarter in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
-
Rhea-AI Summary
AVITA Medical, Inc. (RCEL, AVH) announced an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States. The agreement grants AVITA Medical exclusive rights to market, sell, and distribute PermeaDerm products in the U.S. The gross margin from the sale of PermeaDerm is expected to be 50% of the average sales price. The partnership aims to expand AVITA Medical's portfolio and address unmet patient needs, with the potential for renewal after five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
-
Rhea-AI Summary
AVITA Medical, Inc. (RCEL, AVH) announced preliminary unaudited financial highlights for Q4 and full-year 2023. Commercial revenue for Q4 2023 is expected to be approximately $14.1 million, an increase of 50% compared to the same period in 2022. Full-year 2023 commercial revenue is expected to be approximately $49.8 million, with an 46% increase over 2022. Gross margin for 2023 is expected to be approximately 84.5%. The company also provided financial guidance for Q1 and full-year 2024, and announced the completion of patient enrollment in its post-market study, TONE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
Rhea-AI Summary
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced that CEO Jim Corbett will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The company focuses on regenerative medicine for skin restoration and will provide a live audio webcast of the presentation on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
AVITA Medical Inc

Nasdaq:RCEL

RCEL Rankings

RCEL Stock Data

253.98M
24.81M
0.66%
28.08%
2.83%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Valencia

About RCEL

avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company’s lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.